SECsense Logo

Carisma Therapeutics Inc. 8-K Report: Key Updates for Investors - Jan 6, 2025

$CARM
Form 8-K
Filed on: 2025-01-10
Source
Carisma Therapeutics Inc. 8-K Report: Key Updates for Investors - Jan 6, 2025

Based on the provided section of the financial report, here are the key pieces of information extracted:

  1. Company Identification:
  • Name: Carisma Therapeutics Inc.
  • CIK: 0001485003
  • SEC File Number: 001-36296
  • EIN: 26-2025616
  • Address: 3675 Market Street, Suite 401, Philadelphia, PA 19104
  • Phone: 267-491-6422
  1. Filing Type:
  • Form: 8-K (This form is used to report unscheduled material events or corporate changes).
  1. Filing Date:
  • Date of Report: January 6, 2025
  1. Financial Metrics:
  • Common Stock Par Value: $0.001
  • Ticker Symbol: CARM
  • Stock Exchange: NASDAQ
  1. Context and Measurement:
  • Context ID: AsOf2025-01-06
  • Period: The financial data pertains to a single day, January 6, 2025.
  • Currency: USD (United States Dollar)
  • Unit of Measure: Shares
  1. Schema Reference:
  • The document references a schema file named "carm-20250106.xsd" which likely contains definitions for the data formats used in the report.

Insights:

  • This 8-K filing presents important information about a corporate event or update for Carisma Therapeutics on January 6, 2025. The mention of common stock suggests the company may have had significant changes in their stock structure, investor relations, or corporate governance.
  • The use of the 8-K form indicates that the company is actively communicating material changes to stakeholders, which is crucial for transparency and compliance with SEC regulations.
  • The fact that this report is dated in the future (2025) suggests it could be part of a planned release or a forward-looking statement.

Overall, the document provides essential identification, financial metrics, and regulatory compliance information relevant to stakeholders and investors monitoring Carisma Therapeutics Inc.